{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:53:16Z","timestamp":1792857196459,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T00:00:00Z","timestamp":1708128000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA250972"],"award-info":[{"award-number":["P01-CA250972"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.nucmedbio.2023.108329","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:53:01Z","timestamp":1676289181000},"page":"108329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Theranostic cobalt-55\/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry"],"prefix":"10.1016","volume":"118-119","author":[{"given":"Wilson","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aluicio-Sarduy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey A.","family":"Houson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Barnhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Tekin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Jeffery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Weichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall E.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2023.108329_bb0005","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0010","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1118\/1.2229428","article-title":"Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution","volume":"33","author":"Uusij\u00e4rvi","year":"2006","journal-title":"Med Phys"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0015","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/diagnostics11071235","article-title":"Production, purification, and applications of a potential theranostic pair: Cobalt-55 and Cobalt-58m","volume":"11","author":"Barrett","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ph10020056","article-title":"The beginning and development of the theranostic approach in nuclear medicine, as exemplified by the radionuclide pair 86Y and 90Y","volume":"10","author":"R\u00f6sch","year":"2017","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0025","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2967\/jnumed.114.137182","article-title":"Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy","volume":"55","author":"Thisgaard","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/ph7040464","article-title":"In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study","volume":"7","author":"Maschauer","year":"2014","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1021\/bc900151z","article-title":"Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors","volume":"20","author":"Alshoukr","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0040","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/1535-7163.MCT-07-0164","article-title":"Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting","volume":"6","author":"Falciani","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0045","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/j.biocel.2004.04.013","article-title":"Internalization and trafficking of neurotensin via NTS3 receptors in HT29 cells","volume":"36","author":"Morinville","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0050","first-page":"3","article-title":"Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy","author":"Wu","year":"2013","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0969-8051(01)00284-0","article-title":"Biodistribution and catabolism of 18F-labeled neurotensin(8\u201313) analogs","volume":"29","author":"Bergmann","year":"2002","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0060","author":"Janssen"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0065","first-page":"8","article-title":"Insightful backbone modifications preventing proteolytic degradation of neurotensin analogs improve NTS1-induced protective hypothermia","author":"Previti","year":"2020","journal-title":"<sb:contribution><sb:title>Front <\/sb:title><\/sb:contribution><sb:host><sb:issue><sb:series><sb:title>Chem<\/sb:title><\/sb:series><\/sb:issue><\/sb:host>"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0070","article-title":"Excitation function of 54Fe(p, \u03b1)51Mn from 9.5 MeV to 18 MeV","volume":"1021","author":"Lin","year":"2022","journal-title":"Nuclear PhysA"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0075","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.apradiso.2017.09.005","article-title":"Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets","volume":"130","author":"Valdovinos","year":"2017","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0080","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1118\/1.3608905","article-title":"Production and dosimetric aspects of the potent auger emitter 58mCo for targeted radionuclide therapy of small tumors","volume":"38","author":"Thisgaard","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0085","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.3390\/pharmaceutics14122724","article-title":"PET imaging of the neurotensin targeting peptide NOTA-NT-20.3 using Cobalt-55, Copper-64 and Gallium-68","volume":"14","author":"Houson","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0090","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2967\/jnumed.121.263253","article-title":"MIRD Pamphlet No. 27: MIRDcell V3, a revised software tool for multicellular dosimetry and bioeffect modeling","volume":"63","author":"Katugampola","year":"2022","journal-title":"J Nuclear Med"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0095","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.2967\/jnumed.113.131037","article-title":"MIRD Pamphlet No. 25: MIRDcell V2.0 software tool for dosimetric analysis of biologic response of multicellular populations","volume":"55","author":"Vaziri","year":"2014","journal-title":"J Nuclear Med"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0253439","article-title":"An image-based flow cytometric approach to the assessment of the nucleus-to-cytoplasm ratio","volume":"16","author":"Sebastian","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0105","series-title":"Radionuclide transformations - energy and intensity of emissions","year":"1983"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0110","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0115","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2014standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nuclear Med"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0120","unstructured":"A.L.F. Lazzarini A.L.F. Lazzarini C StudiNucleari E Fermi . ON THE SURVIVAL OF Co(III) COMPLEXES TO DEEXCITATION BY INTERNAL CONVERSION OF THE 5BmCo COORDINATING ATOM n.d.:5."},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0125","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2310\/7290.2015.00025","article-title":"Cyclotron production of high-specific activity 55Co and in vivo evaluation of the stability of 55Co metal-chelate-peptide complexes","volume":"14","author":"Mastren","year":"2015","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0130","first-page":"247","article-title":"Radiation dosimetry of 131I\u201319-iodocholesterol: the pitfalls of using tissue concentration data","volume":"16","author":"Blau","year":"1975","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0135","series-title":"Adult reference computational phantoms: joint ICRP\/ICRU report","year":"2009"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0140","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1088\/0031-9155\/61\/6\/2333","article-title":"A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom","volume":"61","author":"Kostou","year":"2016","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0145","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.2967\/jnumed.119.240366","article-title":"OpenDose: open-access resource for nuclear medicine dosimetry","volume":"61","author":"Chauvin","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0150","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0168-9002(03)01368-8","article-title":"Geant4\u2014a simulation toolkit","volume":"506","author":"Agostinelli","year":"2003","journal-title":"Nucl Instrum Methods Phys Res, Sect A"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0155","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nima.2016.06.125","article-title":"Recent developments in Geant4","volume":"835","author":"Allison","year":"2016","journal-title":"Nucl Instrum Methods Phys Res, Sect A"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0160","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1109\/TNS.2006.869826","article-title":"Geant4 developments and applications","volume":"53","author":"Allison","year":"2006","journal-title":"IEEE Trans Nucl Sci"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0165","doi-asserted-by":"crossref","first-page":"v","DOI":"10.1016\/j.nucmedbio.2017.09.004","article-title":"Consensus nomenclature rules for radiopharmaceutical chemistry \u2014 setting the record straight","volume":"55","author":"Coenen","year":"2017","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acsmedchemlett.9b00462","article-title":"Fluorescence labeling of Neurotensin(8\u201313) via arginine residues gives molecular tools with high receptor affinity","volume":"11","author":"Keller","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0175","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1242\/jcs.113.17.2963","article-title":"Ligand-induced internalization of neurotensin in transfected COS-7 cells: differential intracellular trafficking of ligand and receptor","volume":"113","author":"Vandenbulcke","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0180","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.3390\/cancers14194922","article-title":"Development of a neurotensin-derived 68Ga-labeled PET ligand with high in vivo stability for imaging of NTS1 receptor-expressing tumors","volume":"14","author":"Schindler","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0185","series-title":"Evaluation of the neurotensin receptor-1 as target for molecular imaging and radiotherapy of pancreatic and prostate cancer","author":"Geer","year":"2018"},{"key":"10.1016\/j.nucmedbio.2023.108329_bb0190","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2967\/jnumed.116.185140","article-title":"Proof of therapeutic efficacy of a 177Lu-labeled neurotensin receptor 1 antagonist in a colon carcinoma xenograft model","volume":"58","author":"Schulz","year":"2017","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805123000161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:31:02Z","timestamp":1760848262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805123000161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":38,"alternative-id":["S0969805123000161"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108329","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostic cobalt-55\/58m for neurotensin receptor-mediated radiotherapy in vivo: A pilot study with dosimetry","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2023.108329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108329"}}